Monash University

Embargoed and Restricted Access

Reason: Under embargo until August 2020. After this date a copy can be supplied under Section 51 (2) of the Australian Copyright Act 1968 by submitting a document delivery request through your library

Targeting the ribosome to treat advanced prostate cancer

posted on 2017-08-02, 23:29 authored by RICHARD JOSEPH REBELLO
Metastatic castrate-resistant prostate cancer (mCRPC) remains incurable, highlighting the need for new therapeutic targets. Prostate epithelium is exquisitely sensitive to MYC activity and MYC is universally overexpressed in mCRPC. One key process in cancer cells is to accelerate growth via stimulation of high levels of ribosome biogenesis through regulation of RNA polymerase I (Pol I). This thesis describes preclinical evidence that co-targeting Pol I transcriptional activity and PIM kinases is an effective means of inhibiting MYC-driven prostate cancer. We employ numerous pre-clinical models of PC which shows the efficacy of therapies that combine to target MYC-directed signaling to the ribosome.


Principal supervisor

Luc Furic

Additional supervisor 1

Gail Risbridger

Year of Award


Department, School or Centre

School of Biomedical Sciences (Monash Biomedicine Discovery Institute)

Additional Institution or Organisation

Anatomy and Developmental Biology

Campus location



Doctor of Philosophy

Degree Type



Faculty of Medicine Nursing and Health Sciences